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ABSTRACT 
Tamoxifen is the drug of choice in the treatment of breast cancer. Recent reports show an increased inci-
dence of endometrial carcinoma in patients taking tamoxifen. In this article, we report a case of malignant 
mixed mullerian tumor after tamoxifen use. 
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Tamoxifen therapy is known to increase the risk of 
endometrial carcinoma. Most of these malignancies are 
endometrial adenocarcinma, but occurrence of endome-
trial sarcoma has been reported as well [‎1-‎6]. Here, we 
report a woman who developed a malignant mixed mul-
lerian tumor after use of tamoxifen for 5 years. 
CASE REPORT 
A 72-year-old woman, gravida 6, para 6, live child 
4, was admitted to our gynecologic clinic because of 
post-menopausal vaginal bleeding for two months. Her 
medical history showed a standard radical left mastect-
omy after the diagnosis of left breast cancer at age 60. 
She received an oral dose of 200mg tamoxifen daily for 
5 years. In physical exam, she had a big uterus approx-
imately in size of uterus of a 16-weeks pregnant woman. 
Abdominal ultrasound image showed a big uterine mass 
(3 × 2.9 × 1.8 cm) in endometrial area in association 
with liquid accumulation in adnexae. CT scan showed 
no bone involvement. An endometrial biopsy was ob-
tained which showed a mixture of carcinomatous and 
sarcomatous elements. In sarcomatous component, 
pleomorphic cells with atypical mitoses and bizarre tu-
moral giant cells were observed (Fig 1). In the carcino-
matous part, malignant epithelial cells were arranged in 
tubular structures or cords (Fig 2). The preliminary pa-
thological diagnosis was malignant mixed mullerian 
tumor. We performed laparotomy with a pre-operative 
diagnosis of malignant uterine mass. A total abdominal 
hysterectomy and bilateral salpingo-ophorectomy and 
pelvic lymph node sampling were performed. In gross 
examination, there was a polypoid tumoral mass mea-
suring 5 x 4 cm in diameter which occupied endometrial 
cavity. The tumor invaded full thickness of the myome-
trium. In microscopic examination, tumor consisted of 
tumoral epithelial cells with foci of pleomorphic atypi-
cal spindle cells. Omentum and liver were involved as 
well. The diagnosis of malignant mixed mullerian tumor 
was made. 
DISCUSSION 
Tamoxifen, a partial agonist of estrogen, has been 
widely used in the treatment of breast cancer. In the 
recent yeas, the occurrence of uterine malignancy in 
patients receiving tamoxifen has been identified. These 
malignancies have been reported as adenocarcinoma as 
well as uterine sarcoma. In women not taking tamox-
ifen, fewer cases of uterine malignancies have been ob-
served when compared with those taking the drug. 
Tamoxifen is a complex drug with both agonist and 
antagonist effects on estrogen receptors. This mixture 
agonist and antagonist properties may explain both effi-
cacy and toxicity of tamoxifen. Toxic effects of tamox-
ifen are observable throughout the entire urogenital tract 
including vaginal epithelium, cervix, uterine corpus, 
endometrium an ovaries. Tamoxifen has a proliferative 
effect on endometrial stromal cells and this effect is 
intensified by higher doses of drug as well as a longer 
time of its use [‎7-‎8]. 
Overall, benefits of tamoxifen in the treatment and 
prevention of breast cancer is much higher than its risk 
for uterine malignancies. It should be kept in mind that 
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high-risk patient for endometrial cancer should be iden-
tified before tamoxifen therapy. Also, in patients re-
ceiving tamoxifen, regular uterine sonography in con-
junction with endometrial biopsies would be appropriate 
for early diagnosis of endometrial malignancies. 
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Fig 1. Sarcomatous component of malignant mixed mullerian tumor. 
Fig 2. Carcinomatous element of malignant mixed mullerian tumor. 
